Home/Unicycive Therapeutics/Douglas Jermasek, M.B.A.
DJ

Douglas Jermasek, M.B.A.

EVP, Corporate Strategy

Unicycive Therapeutics

Therapeutic Areas

Unicycive Therapeutics Pipeline

DrugIndicationPhase
Oxylanthanum Carbonate (OLC)Hyperphosphatemia in Chronic Kidney Disease (CKD)NDA Submitted
UNI-494Acute Kidney Injury (AKI)Preclinical